Levofloxacin

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV Infections

Conditions

HIV Infections

Trial Timeline

— → —

NCT ID

NCT00002249

About Levofloxacin

Levofloxacin is a phase 1 stage product being developed by Johnson & Johnson for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00002249. Target conditions include HIV Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002249	Phase 1	Completed	—	—	HIV Infections
NCT00210886	Phase 3	Completed	Oct 1, 2004	Apr 1, 2006	Urinary Tract Infections
NCT00645437	Phase 1	Completed	Oct 1, 2004	Apr 1, 2006	Renal Diseases
NCT00236652	Phase 3	Completed	Nov 1, 2003	Jun 1, 2005	Maxillary Sinusitis
NCT00044473	Phase 3	Completed	Nov 1, 2002	Jul 1, 2003	Otitis Media
NCT00236522	Phase 3	Completed	Oct 1, 2002	Apr 1, 2004	Sinusitis
NCT00034736	Phase 3	Completed	Aug 1, 2002	Jun 1, 2004	Pneumonia
NCT00236821	Phase 3	Completed	Mar 1, 2001	Jun 1, 2002	Pneumonia
NCT00236808	Phase 3	Completed	May 1, 2000	Nov 1, 2001	Prostatitis
NCT00249197	Phase 3	Completed	Jan 1, 1997	Jul 1, 1998	Skin Diseases, Bacterial
NCT00269932	Phase 3	Completed	Aug 1, 1993	May 1, 1994	Bronchitis, Chronic
NCT00249210	Phase 3	Completed	Aug 1, 1993	Jul 1, 1994	Sinusitis
NCT00258089	Phase 3	Completed	Jun 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00258102	Phase 3	Completed	Jan 1, 1993	Jan 1, 1995	Urinary Tract Infections
NCT00257062	Phase 3	Completed	Jan 1, 1993	Apr 1, 1994	Skin Diseases, Infectious
NCT00257036	Phase 2/3	Completed	Jul 1, 1991	Feb 1, 1993	Skin Diseases, Infectious
NCT00257049	Phase 2/3	Completed	Jan 1, 1984	Jan 1, 1995	Pneumonia
NCT00257140	Phase 2/3	Completed	Jun 1, 1931	Jul 1, 1994	Bronchitis

Competing Products

20 competing products in HIV Infections

See all competitors

Product	Company	Stage	Hype Score
AAVLP-HPV + Placebo	2A Pharma	Phase 1	25
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	33
VN-0200	Daiichi Sankyo	Phase 2	52
Micafungin	Astellas Pharma	Pre-clinical	23
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	85
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus	Astellas Pharma	Approved	85
Micafungin	Astellas Pharma	Pre-clinical	23
Micafungin	Astellas Pharma	Phase 1	33
Micafungin + Placebo	Astellas Pharma	Phase 3	77
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Xeruborbactam Oral Prodrug + Ceftibuten	Shionogi	Phase 1	33
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily	Shionogi	Phase 3	77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
GW810781	Shionogi	Phase 2	52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
Cefiderocol	Shionogi	Phase 2	52

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved

Nicotine Gum + Nicotine PatchApproved

galantamineApproved

IbrutinibApproved

Paliperidone ERApproved